<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2566">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646044</url>
  </required_header>
  <id_info>
    <org_study_id>20-214-34</org_study_id>
    <nct_id>NCT04646044</nct_id>
  </id_info>
  <brief_title>A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19</brief_title>
  <official_title>A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nektar Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled,&#xD;
      trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of&#xD;
      bempegaldesleukin (BEMPEG; NKTR-214) in combination with standard of care (SOC) in adult&#xD;
      patients with mild COVID-19 (coronavirus disease 2019). The trial will also define the&#xD;
      recommended phase 2 dose (RP2D) of bempegaldesleukin in patients with mild COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">March 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of BEMPEG/standard of care (SOC) (PK).</measure>
    <time_frame>Approximately 30 days</time_frame>
    <description>Area under the serum concentration-time curve (AUC) of BEMPEG /SOC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of BEMPEG /SOC (PK).</measure>
    <time_frame>Approximately 30 days</time_frame>
    <description>Maximum observed serum concentration (Cmax) of BEMPEG /SOC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of BEMPEG /SOC (PK).</measure>
    <time_frame>Approximately 30 days</time_frame>
    <description>Time to Cmax (Tmax) of BEMPEG /SOC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events.</measure>
    <time_frame>Approximately 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs).</measure>
    <time_frame>Approximately 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs).</measure>
    <time_frame>Approximately 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLT) for BEMPEG.</measure>
    <time_frame>Approximately 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence and levels of anti-drug antibodies directed to BEMPEG.</measure>
    <time_frame>Approximately 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fold change from baseline in absolute lymphocyte count by Central Laboratory.</measure>
    <time_frame>Approximately 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who require supplemental oxygen.</measure>
    <time_frame>Approximately 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the daily collection World Health Organization (WHO) Clinical Progression Scale, an 11-point clinical status ordinal scale.</measure>
    <time_frame>Approximately 30 days</time_frame>
    <description>The WHO Clinical Progression Scale scores and descriptors are as follows:&#xD;
0- Uninfected; no viral RNA detected; 1- Asymptomatic; viral RNA detected; 2- Symptomatic; independent; 3- Symptomatic; assistance needed; 4- Hospitalized, no oxygen therapy; 5- Hospitalized; oxygen by mask or nasal prongs ; 6- Hospitalized; oxygen by non-invasive ventilation or high-flow; 7- Intubation and mechanical ventilation, PaO2/FiO2 ≥ 150 or SpO2/FiO2 ≥ 200; 8- Mechanical ventilation, PaO2/FiO2 &lt; 150 (SpO2/FiO2 &lt; 200) or vasopressors; 9- Mechanical ventilation, PaO2/FiO2 &lt; 150 and vasopressors, dialysis, or ECMO; 10- Death&#xD;
Abbreviations: ECMO = extracorporeal membrane oxygenation; FiO2 = fraction of inspired oxygen; PaO2 = partial pressure of arterial oxygen; SpO2 = oxygen saturation If hospitalized for isolation only, record status as for ambulatory patient. Source: WHO 2020.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid-19</condition>
  <condition>Coronavirus Disease 2019</condition>
  <arm_group>
    <arm_group_label>Bempegaldesleukin IV + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bempegaldesleukin</intervention_name>
    <description>Administered as an intravenous infusion</description>
    <arm_group_label>Bempegaldesleukin IV + Standard of Care</arm_group_label>
    <other_name>NKTR-214</other_name>
    <other_name>BEMPEG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care Treatment for COVID-19 Infection</description>
    <arm_group_label>Bempegaldesleukin IV + Standard of Care</arm_group_label>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as an intravenous infusion</description>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, age 18 years or older on the day of signing the informed&#xD;
             consent form.&#xD;
&#xD;
          -  Agrees to admission to an in-patient facility for monitoring from Days 1 to 8,&#xD;
             inclusive.&#xD;
&#xD;
          -  Symptoms of mild illness with COVID-19 without shortness of breath, dyspnea, or&#xD;
             clinical signs indicative of more serious COVID-19.&#xD;
&#xD;
          -  Laboratory confirmed SARS-CoV-2 infection within 4 days prior to the screening visit&#xD;
             or during the 7-day screening period.&#xD;
&#xD;
          -  Respiratory rate &lt; 20 breaths per minute, heart rate &lt; 90 beats per minute (bpm).&#xD;
&#xD;
          -  Oxygen saturation by pulse oximetry &gt; 93% on room air.&#xD;
&#xD;
          -  Body mass index &lt; 35 kg/m2.&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min.&#xD;
&#xD;
          -  Alanine transaminase (ALT) or aspartate transaminase (AST) &lt; 2 x upper limit of normal&#xD;
             (ULN) and total bilirubin &lt; 1.5 x ULN.&#xD;
&#xD;
          -  Agrees to not participate in another clinical trial for the treatment of COVID-19&#xD;
             while on study unless the patient's condition has worsened and is considered to be&#xD;
             moderate, severe, or critical by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Shortness of breath, hypoxia, or signs of serious lower airway disease.&#xD;
&#xD;
          -  C-reactive protein, lactate dehydrogenase (LDH), or interleukin-6 (IL-6) &gt; 1.5 x ULN.&#xD;
&#xD;
          -  D-dimer or ferritin &gt; 1.5 x ULN.&#xD;
&#xD;
          -  Imminently requiring, or currently on, mechanical ventilation or extracorporeal&#xD;
             membrane oxygenation (ECMO).&#xD;
&#xD;
          -  Systolic blood pressure &lt; 90 mm Hg or diastolic blood pressure &lt; 60 mm Hg.&#xD;
&#xD;
          -  Evidence of acute respiratory distress syndrome (ARDS) or systemic inflammatory&#xD;
             response syndrome (SIRS)/shock.&#xD;
&#xD;
          -  Known cardiovascular history, including unstable or deteriorating cardiac disease.&#xD;
&#xD;
          -  Autoimmune disease.&#xD;
&#xD;
          -  History of pulmonary embolism (PE), deep vein thrombosis (DVT), or prior clinically&#xD;
             significant venous or non-cerebrovascular accident/transient ischemic attack arterial&#xD;
             thromboembolic event.&#xD;
&#xD;
          -  Central nervous system disease or dysfunction.&#xD;
&#xD;
          -  Requirement for &gt; 2 anti-hypertensive medications.&#xD;
&#xD;
          -  Unwilling to refrain from alcohol consumption from Day 1 of admission to the&#xD;
             in-patient facility until discharge from the facility.&#xD;
&#xD;
          -  Adrenal insufficiency.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Nektar Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nektar</last_name>
    <phone>855-482-8676</phone>
    <email>studyinquiry@nektar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Praveena Raman</last_name>
    <email>medicalaffairs@nektar.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nektar</last_name>
      <email>studyinquiry@nektar.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nektar</last_name>
      <email>studyinquiry@nektar.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 14, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BEMPEG</keyword>
  <keyword>Bempegaldesleukin</keyword>
  <keyword>CD122</keyword>
  <keyword>CD122-Biased Agonist</keyword>
  <keyword>CD122-Biased Cytokine</keyword>
  <keyword>Coronavirus Disease</keyword>
  <keyword>COVID-19</keyword>
  <keyword>IL-2 receptor agonist</keyword>
  <keyword>Lymphopenia</keyword>
  <keyword>Mild COVID</keyword>
  <keyword>NKTR-214</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Severe Acute Respiratory Syndrome Coronavirus 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

